{"product_id":"sinocare-business-model-canvas","title":"Sinocare Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSinocare BMC: Diabetes-care value, scaling partners, device+consumables monetization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Sinocare’s business model—this concise Business Model Canvas shows how the company creates value in diabetes care, scales via partner networks, and monetizes through device + consumable sales and service contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Hospital and Clinical Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare partners with over 400 tertiary hospitals and 1,200 community health centers to embed its Point-of-Care Testing devices into clinical workflows, supporting 85 ongoing clinical trials for new biosensors and generating \u0026gt;30,000 clinician feedback points yearly for product refinement; by 2025 these collaborations underpin integrated chronic disease management programs covering ~12 million patients within national healthcare systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Retail Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare relies on a network of pharmacy chains and medical-device distributors to supply products in 135+ countries; in 2024 channel sales accounted for about 78% of revenue, per company filings. \u003c\/p\u003e\n\u003cp\u003eThrough Trividia Health, partnerships with US retailers like CVS and Walgreens drive market share—retail placements and distributor logistics support high-volume consumable turnover, with consumables representing roughly 62% of group sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Digital Platform Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with Alibaba, JD.com, and Amazon give Sinocare flagship stores that drove ~28% of global direct-to-consumer revenue in 2024 (¥1.2bn RMB), while platform analytics reduced CAC 18% by targeting repeat buyers.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 these alliances add cross-platform health-data sharing with top fitness apps, enabling aggregated glucose-trend insights from ~3.5M users to inform promotions and product roadmaps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Academic Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSinocare partners with top Chinese universities and biosensor institutes to advance non-invasive and continuous glucose monitoring, fueling its third-generation sensor pipeline and securing early IP—R\u0026amp;D spend rose 22% to RMB 412M in 2024 to support these collaborations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly IP access reduces time-to-market vs global med-tech firms\u003c\/li\u003e\n\u003cli\u003eCollaborations supported 3 patent filings on non-invasive sensors in 2024\u003c\/li\u003e\n\u003cli\u003eAcademic trials contributed to a 15% improvement in sensor accuracy in 2023–24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Raw Material Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMaintaining stable ties with specialized chemical and electronic suppliers is critical for Sinocare’s biosensor strips; in 2024 Sinocare reported raw-materials as ~18% of COGS, so supplier quality directly affects margin and sensor precision.\u003c\/p\u003e\n\u003cp\u003eThese partners secure enzyme reagent stability and micro-electrode quality through joint QC protocols and long-term contracts that reduced input price volatility by ~6% YoY in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRaw materials ≈18% of COGS (2024)\u003c\/li\u003e\n\u003cli\u003eLong-term contracts cut input volatility ~6% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eJoint QC on enzymes and micro-electrodes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSinocare: 400+ hospitals, 1,200 centers, ¥1.2bn D2C, 78% channels, 62% consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare’s key partners—400+ tertiary hospitals, 1,200 community centers, pharmacy chains, Trividia\/US retailers, Alibaba\/JD\/Amazon, top universities, and critical suppliers—drive clinical validation, 85 trials, ~12M chronic-care patients by 2025, channel sales ≈78% revenue (2024), consumables ≈62% group sales (2024), D2C ¥1.2bn (≈28% D2C, 2024), R\u0026amp;D RMB412M (2024), raw materials ≈18% COGS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTertiary hospitals\u003c\/td\u003e\n\u003ctd\u003eCount\u003c\/td\u003e\n\u003ctd\u003e400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommunity centers\u003c\/td\u003e\n\u003ctd\u003eCount\u003c\/td\u003e\n\u003ctd\u003e1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel sales\u003c\/td\u003e\n\u003ctd\u003eShare\u003c\/td\u003e\n\u003ctd\u003e≈78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003eShare of sales\u003c\/td\u003e\n\u003ctd\u003e≈62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eD2C (e‑commerce)\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e¥1.2bn (≈28% D2C)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eSpend\u003c\/td\u003e\n\u003ctd\u003eRMB412M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials\u003c\/td\u003e\n\u003ctd\u003eCOGS share\u003c\/td\u003e\n\u003ctd\u003e≈18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Sinocare outlining customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure, and metrics—reflecting its real-world diabetes diagnostics and chronic disease management strategy with competitive analysis, SWOT-linked insights, and investor-ready narrative for presentations and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Sinocare's diabetes-care business model into a digestible one-page snapshot, saving hours of structuring while enabling fast comparison, team collaboration, and quick executive review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R and D in Biosensing Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare focuses R and D on refining continuous glucose monitoring (CGM) and multi-indicator platforms, targeting ±8% MARD accuracy and 14‑day wear times; R and D spend rose to RMB 420M in 2024 (up 28% YoY). \u003c\/p\u003e\n\u003cp\u003eBy end-2025 teams pivoted to embedded AI predictive analytics—pilot shows 12% reduction in hypoglycemia alerts and a 9% uplift in retention in 3,000‑patient trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Volume Precision Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare runs automated production lines producing over 3 billion blood glucose test strips annually (2024 revenue from strips ~RMB 1.1bn), optimizing yield and unit cost to compete on price while meeting CE, FDA and NMPA medical standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Brand Positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare runs global campaigns to shift from budget meter maker to high-tech health-management leader, spending about $18M in 2024 on marketing and raising brand ad recall 22% in target markets.\u003c\/p\u003e\n\u003cp\u003eThey attend major medical forums (e.g., ESC 2024, ADA 2024), run diabetes awareness programs reaching 12M people in 2024, and localize messaging and regulatory submissions across Asia, Europe and the Americas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Ecosystem Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSinocare operates Sinocare Cloud and mobile apps for chronic disease care, investing ~RMB 120m in 2024 R\u0026amp;D for software engineering, data security, and UX to support 4.2m users and 35,000 linked providers for metabolic monitoring.\u003c\/p\u003e\n\u003cp\u003eThe ecosystem enables real-time glucose and BP data sharing, reducing average hospital visits by 18% and increasing treatment adherence by 22% in 2024 pilot studies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB 120m R\u0026amp;D 2024\u003c\/li\u003e\n\u003cli\u003e4.2m users, 35,000 providers\u003c\/li\u003e\n\u003cli\u003e18% fewer hospital visits (pilot)\u003c\/li\u003e\n\u003cli\u003e22% higher adherence (pilot)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSinocare's legal and quality teams continuously manage global medical-device regulations, keeping products compliant with FDA (US), CE (EU) and NMPA (China) standards to preserve access to markets representing \u0026gt;60% of revenue (2024 sales ¥1.8bn). \u003c\/p\u003e\n\u003cp\u003eThey run regular audits and stage-gate quality checks—over 1,200 inspections in 2024—ensuring traceability and patient safety across R\u0026amp;D, manufacturing, and distribution. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCompliant with FDA, CE, NMPA\u003c\/li\u003e\n\u003cli\u003e2024 revenue exposure \u0026gt;60%\u003c\/li\u003e\n\u003cli\u003e¥1.8bn 2024 sales\u003c\/li\u003e\n\u003cli\u003e1,200+ audits in 2024\u003c\/li\u003e\n\u003cli\u003eStage-gate QC at every production step\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSinocare: ¥1.8B sales, 3B+ strips, 4.2M users — leading CGM, R\u0026amp;D and global approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare runs R\u0026amp;D to hit ±8% MARD and 14‑day CGM wear (RMB 420M R\u0026amp;D, 2024), automated lines making \u0026gt;3bn strips (RMB 1.1bn strips revenue, 2024), Sinocare Cloud for 4.2m users\/35k providers (RMB 120M SW R\u0026amp;D, 2024), global regs (FDA\/CE\/NMPA) with 1,200+ audits and ¥1.8bn sales (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSW R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eRMB 120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrip production\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3bn units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrip revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal sales\u003c\/td\u003e\n\u003ctd\u003e¥1.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUsers \/ Providers\u003c\/td\u003e\n\u003ctd\u003e4.2M \/ 35k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAudits\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas previewed here is the actual Sinocare document you’ll receive—no mockup or sample—presented exactly as in the final file; upon purchase you’ll get this same professional, ready-to-edit canvas in full. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749650575737,"sku":"sinocare-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sinocare-business-model-canvas.png?v=1772216380","url":"https:\/\/matrixbcg.com\/products\/sinocare-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}